SARDA PROTEINS LTD.

Sarda Proteins Limited's Board of Directors has approved a rights issue of equity shares, aiming to raise up to ₹10,000 lakhs (₹100 crore). The board also approved the Draft Letter of Offer (DLOF) for the issue and constituted a Rights Issue Committee. Additionally, the company noted the resignation of non-executive director Mr. Gunvantray Jayantilal Zaladi, effective August 5, 2026, due to personal reasons and pre-occupations. The record date for the rights issue will be intimated separately.

Sarda Proteins Limited's Board of Directors has approved the issuance of equity shares on a rights basis, aiming to raise up to ₹100 crore. The company will file a Draft Letter of Offer (DLOF) with SEBI and stock exchanges. A Rights Issue Committee has been formed to oversee the process. The board also noted the resignation of non-executive director Mr. Gunvantray Jayantilal Zaladi due to personal reasons. The record date for the rights issue will be announced separately.

Sarda Proteins Limited announced the resignation of non-executive director Mr. Gunvantray Jayantilal Zaladi, effective August 5, 2026, due to personal reasons. The Board of Directors also approved a Rights Issue of equity shares not exceeding ₹10,000 lakhs (₹100 Crore). A Rights Issue Committee has been formed to oversee the process, and necessary intermediaries have been appointed. The company will separately announce the record date for the issue.

Sarda Proteins Ltd has resubmitted its audited financial results for the quarter and financial year ended March 31, 2026. The revision was necessitated by clerical errors related to the booking of interest income and the reclassification of share warrants as equity. The company assures that these corrections are purely clerical and have no material impact on the overall financial position. The revised outcome of the Board Meeting and financial results replace the earlier submission made on April 30, 2026. The Board Meeting took place from 4:30 PM to 5:15 PM.

Sarda Proteins Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item is to consider and approve proposals for raising funds. This could be achieved through various instruments including equity shares, convertible bonds, debentures, warrants, or preference shares. The company plans to utilize permissible modes such as rights issues, private placements, preferential issues, or qualified institutional placements, in compliance with relevant SEBI and Companies Act regulations.

Sarda Proteins Ltd announced that its Board of Directors, in a meeting held on July 4, 2026, approved a change in the company's name. The new name is subject to approval from the Central Registration Centre (CRC), Ministry of Corporate Affairs. Consequently, the Memorandum of Association and Articles of Association of the company will be altered. This agenda item was considered and approved following the earlier board meeting outcome submission.

Sarda Proteins Ltd has issued an addendum to its Extraordinary General Meeting (EGM) notice, originally dated July 4, 2026. The addendum, dispatched on July 15, 2026, introduces three new agenda items for shareholder approval. The EGM is scheduled for July 30, 2026, via Video Conferencing. The new items include the appointment of M/s A H MANDALIYA & ASSOCIATES. as Statutory Auditors to fill a casual vacancy and for their first term of five years from April 1, 2026, to March 31, 2031. The original EGM notice remains in effect, to be read in conjunction with this addendum.

Sarda Proteins Limited announced the appointment of Ms. Minal Surendra Jain as an Independent Woman Director for a term of five years, subject to shareholder approval. The board meeting also approved the Unaudited Standalone Financial Results for the quarter ended June 30, 2026, the shifting of the registered office within Alwar, Rajasthan, and the establishment of a new corporate office in Rajkot, Gujarat. Additionally, committees including Audit, Nomination and Remuneration, and Stakeholders' Relationship were reconstituted.

Sarda Proteins Limited held a Board of Directors meeting on July 15, 2026. The board approved the Unaudited Standalone Financial Results for the quarter ended June 30, 2026. Key decisions included shifting the registered office within Alwar, Rajasthan, and establishing a new corporate office in Rajkot, Gujarat. Additionally, Ms. Minal Surendra Jain was appointed as an Independent Women Director for a five-year term, subject to shareholder approval. The Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee were also reconstituted.

Sarda Proteins Limited held a Board of Directors meeting on July 15, 2026. The board approved the unaudited standalone financial results for the quarter ended June 30, 2026. Key decisions included shifting the registered office within Alwar, Rajasthan, and establishing a new corporate office in Rajkot, Gujarat. Additionally, Ms. Minal Surendra Jain was appointed as an Independent Women Director for a five-year term, subject to shareholder approval. The Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee were also reconstituted.